Description: Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
Home Page: www.anixa.com
ANIX Technical Analysis
3150 Almaden Expressway
San Jose,
CA
95118
United States
Phone:
408 708 9808
Officers
| Name | Title |
|---|---|
| Dr. Amit Kumar Ph.D. | Chairman & CEO |
| Mr. Michael J. Catelani CPA, MBA | Pres, COO, CFO & Corp. Sec. |
| Mr. John Roop | Sr. VP of Engineering |
| Mr. Thomas Schlumpberger Ph.D. | Exec. VP of Diagnostics |
| Dr. Pamela D. Garzone Ph.D. | Chief Devel. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3718 |
| Price-to-Sales TTM: | 156.9819 |
| IPO Date: | 1987-01-01 |
| Fiscal Year End: | October |
| Full Time Employees: | 4 |